<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Metabolex Inc.</title><link href="http://diabetesinfoandtreatment.com/topic/metabolex-inc" rel="alternate"></link><id>http://diabetesinfoandtreatment.com/topic/metabolex-inc</id><updated>2010-11-02T12:39:16Z</updated><entry><title>J&amp;J Subsidiary Joins the Diabetes Fray</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/jj-subsidiary-joins-diabetes-fray-3486520a" rel="alternate"></link><updated>2010-11-02T12:06:14Z</updated><author><name>SeekingAlpha</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/type-2-diabetes/jj-subsidiary-joins-diabetes-fray-3486520a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Mergers and Acquisitions"></category><category term="Autoimmune Disorders"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 1 Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Iceland"></category><category term="Norway"></category><category term="Denmark"></category><category term="Finland"></category><category term="Sweden"></category><category term="California"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Johnson &amp; Johnson"></category><category term="Forest Laboratories Inc."></category><category term="Ortho-McNeil Inc."></category><category term="Sanofi-Aventis SA"></category><category term="Nordic Countries"></category><category term="Clinical Immunology"></category><category term="Hayward"></category><category term="Hart-Scott-Rodino Act"></category><category term="Victoza"></category><category term="Metabolex Inc."></category><category term="Diamyd Medical"></category><category term="Martin Fitchet"></category></entry><entry><title>Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes</title><link href="http://diabetesinfoandtreatment.com/diabetes/sanofiaventis-metabolex-enter-exclusive-worldwide-licensing-agreement-oral-antidiabetic-treat-type-ii-diabetes-3515691a" rel="alternate"></link><updated>2010-11-02T12:39:16Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/sanofiaventis-metabolex-enter-exclusive-worldwide-licensing-agreement-oral-antidiabetic-treat-type-ii-diabetes-3515691a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New York"></category><category term="U.S. Securities and Exchange Commission"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="France"></category><category term="Western Europe"></category><category term="Sanofi-Aventis SA"></category><category term="Paris (France)"></category><category term="Euronext"></category><category term="Hart-Scott-Rodino Act"></category><category term="Private Securities Litigation Reform Act"></category><category term="Metabolex Inc."></category><category term="Pierre Chancel"></category></entry><entry><title>J&amp;J cuts 2 deals for diabetes treatment</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/jj-cuts-2-deals-diabetes-treatment-970611a" rel="alternate"></link><updated>2010-06-22T07:16:18Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-06-22:/type-2-diabetes/jj-cuts-2-deals-diabetes-treatment-970611a/</id><summary type="html">&lt;div id="subtitle"&gt;J&amp;amp;J licenses late-stage Type 2 diabetes drug from Diamyd; gets preclincal drugs from &lt;a title="Metabolex Inc." href="/topic/Metabolex+Inc." &gt;Metabolex&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;p&gt;A unit of Johnson &amp;amp; Johnson has partnered with a Nordic pharmaceutical to develop a potential treatment for Type 1 diabetes, the company said Monday.&lt;/p&gt;&lt;p&gt;Sweeden's &lt;a title="Diamyd Medical" href="/topic/Diamyd+Medical" &gt;Diamyd Medical&lt;/a&gt; AB is conducting late-stage clinical tests on the drug, which is...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="California"></category><category term="Europe"></category><category term="Ortho-McNeil Inc."></category><category term="Nordic Countries"></category><category term="Hayward"></category><category term="Janssen LP"></category><category term="Metabolex Inc."></category><category term="Diamyd Medical"></category></entry><entry><title>Metabolex Announces Positive Phase 1 Clinical Trial Results of MBX-2982</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/metabolex-announces-positive-phase-1-clinical-trial-results-mbx2982-3012827a" rel="alternate"></link><updated>2010-10-24T09:16:55Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-24:/type-2-diabetes/metabolex-announces-positive-phase-1-clinical-trial-results-mbx2982-3012827a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Prediabetes"></category><category term="Type 2 Diabetes"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Ortho-McNeil Inc."></category><category term="American Diabetes Association"></category><category term="International Diabetes Federation"></category><category term="Metabolex Inc."></category><category term="Harold Van Wart"></category></entry><entry><title>Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982</title><link href="http://diabetesinfoandtreatment.com/diabetes/metabolex-announces-positive-results-phase-1a-clinical-trial-mbx2982-2950536a" rel="alternate"></link><updated>2010-10-23T16:02:58Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-23:/diabetes/metabolex-announces-positive-results-phase-1a-clinical-trial-mbx2982-2950536a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Ortho-McNeil Inc."></category><category term="American Diabetes Association"></category><category term="International Diabetes Federation"></category><category term="Byetta"></category><category term="Metabolex Inc."></category><category term="CODHy Conference"></category><category term="Chuck McWherter"></category><category term="Harold Van Wart"></category></entry></feed>
